Hypertriglyceridaemia: Aetiology, Complications and Management

References

• Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999; 99(22): 2852–2854.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Krauss RM, Alaupovic P. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: Clinical aspects. Clin Cardiol 1999; 22(6 Suppl): II15–II20.
   PubMed Web of Science ®Google Scholar
• Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: Genetics, lipid uptake, and regulation. J Lipid Res 2002; 43(12): 1997–2006.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Kersten S. Modulation of plasma TG lipolysis by angiopoietin-like proteins and GPIHBP1. Biochim Biophys Acta 2010. DOI 10.1016/j.bbalip2009.12.015
   Google Scholar
• Wang J, Cao H, Ban MR, et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 2007; 27(11): 2450–2455.
   PubMed Web of Science ®Google Scholar
• Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins: An integrated approach to mechanisms and disorders. N Engl J Med 1967; 276(1): 34–42.
   PubMed Web of Science ®Google Scholar
• Pouwels ED, Blom DJ, Firth JC, Henderson HE, Marais AD. Severe hypertriglyceridaemia as a result of familial chylomicronaemia: The Cape Town experience. S Afr Med J 2008; 98(2): 105–108.
   PubMed Web of Science ®Google Scholar
• Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: Working toward clinical application. Hum Gene Ther 2005; 16(11): 1276–1286.
   PubMed Web of Science ®Google Scholar
• Ross CJ, Twisk J, Meulenberg JM, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1 -mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther 2004; 15(9): 906–919.
   PubMed Web of Science ®Google Scholar
• Fojo SS, Baggio G, Gabelli C, et al. Apolipoprotein C-II deficiency: identification of a structural variant ApoC-II Padova. Biochem Biophys Res Commun 1988; 154(1): 73–79.
   PubMed Web of Science ®Google Scholar
• Fojo SS, Lohse P, Parrott C, et al. A nonsense mutation in the apolipoprotein C-IIPadova gene in a patient with apolipoprotein C-II deficiency. J Clin Invest 1989; 84(4): 1215–1219.
   PubMed Web of Science ®Google Scholar
• Fojo SS, De Gennes JL, Beisiegel U, et al. Molecular genetics of apoC-II and lipoprotein lipase deficiency. Adv Exp Med Biol 1991; 285: 329–333.
   PubMedGoogle Scholar
• Beil FU, Fojo SS, Brewer HB, Jr., Greten H, Beisiegel U. Apolipoprotein C-II deficiency syndrome due to apo C-IIHamburg: Clinical and biochemical features and HphI restriction enzyme polymorphism. Eur J Clin Invest 1992; 22(2): 88–95.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Huang Y, Rall SC, Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): Questions, quandaries, and paradoxes. J Lipid Res 1999; 40(11): 1933–1949.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Byrnes P, Jones S, Marais AD. Dysbetalipoproteinaemia: Clinical and pathophysiological features. S Afr Med J 2002; 92(11): 892–897.
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu XQ, Rall SC, Jr., Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J Biol Chem 1998; 273(28): 17483–17490.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ban MR, Hsueh N, et al. A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. Hum Mol Genet 2009; 18(21): 4189–4194.
   PubMed Web of Science ®Google Scholar
• Marcais C, Verges B, Charriere S, et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest 2005; 15(10): 2862–2869.
   Web of Science ®Google Scholar
• Priore OC, Tarugi P, Calandra S, et al. A novel sequence variant in APOA5 gene found in patients with severe hypertriglyceridemia. Atherosclerosis 2006; 188(1): 215–217.
   PubMed Web of Science ®Google Scholar
• Van Dijk KW, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: Synergistic actors in triglyceride metabolism? Curr Opin Lipidol 2004; 15(3): 239–246.
   PubMed Web of Science ®Google Scholar
• Cefalu AB, Noto D, Arpi ML, et al. Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab 2009; 94(11): 4584–4590.
   PubMed Web of Science ®Google Scholar
• Peterfy M, Ben Zeev O, Mao HZ, et al. Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia. Nat Genet 2007; 39(12): 1483–1487.
   PubMed Web of Science ®Google Scholar
• Beigneux AP, Weinstein MM, Davies BS, et al. GPIHBP1 and lipolysis: An update. Curr Opin Lipidol 2009; 20(3): 211–216.
   PubMed Web of Science ®Google Scholar
• Beigneux AP, Franssen R, Bensadoun A, et al. Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol 2009; 29(6): 956–962.
   PubMed Web of Science ®Google Scholar
• Wang J, Hegele RA. Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis 2007; 6: 23.
   PubMed Web of Science ®Google Scholar
• Hegele RA. Monogenic dyslipidemias: Window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001; 69(6): 1161–1177.
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Schrott HG, Hazzard WR, Bierman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52(7): 1544–1568.
   PubMed Web of Science ®Google Scholar
• Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: An up-date. Vasc Health Risk Manag 2007; 3(6): 877–886.
   PubMedGoogle Scholar
• Eichenbaum-Voline S, Olivier M, Jones EL, et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2004; 24(1): 167–174.
   PubMed Web of Science ®Google Scholar
• Pajukanta P, Lilja HE, Sinsheimer JS, et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 2004; 36(4): 371–376.
   PubMed Web of Science ®Google Scholar
• Naukkarinen J, Ehnholm C, Peltonen L. Genetics of familial combined hyperlipidemia. Curr Opin Lipidol 2006; 17(3): 285–290.
   PubMed Web of Science ®Google Scholar
• Naukkarinen J, Nilsson E, Koistinen HA, et al. Functional variant disrupts insulin induction of USF1: Mechanism for USF1-associated dyslipidemias. Circ Cardiovasc Genet 2009; 2(5): 522–529.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Pollex RL. Hypertriglyceridemia: Phenomics and genomics. Mol Cell Biochem 2009; 326(1–2): 35–43.
   PubMed Web of Science ®Google Scholar
• Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73(4): 259–264.
   PubMed Web of Science ®Google Scholar
• Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: Presentation and management. Curr Opin Lipidol 2009; 20(6): 497–504.
   PubMed Web of Science ®Google Scholar
• Sharma P, Lim S, James D, Orchard RT, Horne M, Seymour CA. Pancreatitis may occur with a normal amylase concentration in hypertriglyceridaemia. BMJ 1996; 313(7067): 1265–1266
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Kimura S, Fujimoto K, et al. A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. Ther Apher Dial 2008; 12(6): 509–513.
   PubMed Web of Science ®Google Scholar
• Chen JH, Yeh JH, Lai HW, Liao CS. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10(15): 2272–2274.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77(14): 1179–1184.
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H. Role of triglycerides in coronary artery disease: Lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992; 70(19): 10H–13H.
   PubMed Web of Science ®Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3(2): 213–219.
   PubMedGoogle Scholar
• Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298(3): 309–316.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: Do we need to revisit the oral triglyceride tolerance test? Clin Chem 2008; 54(1): 11–13.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341 (6): 410–418.
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260(5): 641–651.
   PubMed Web of Science ®Google Scholar
• Yuan G, Al Shali KZ, Hegele RA. Hypertriglyceridemia: Its etiology, effects and treatment. CMAJ 2007; 176(8): 1113–1120.
   PubMed Web of Science ®Google Scholar
• Brunzell JD. Clinical practice: Hypertriglyceridemia. N Engl J Med 2007; 357(10): 1009–1017.
   PubMed Web of Science ®Google Scholar
• Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: Clinical and mechanistic perspectives. Atherosclerosis 2008; 197(1): 12–24.
   PubMed Web of Science ®Google Scholar
• Khan S, Minihane AM, Talmud PJ, et al. Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res 2002; 43(6): 979–985.
   PubMed Web of Science ®Google Scholar
• Calder PC, Yaqoob P. Understanding omega-3 polyunsaturated fatty acids. Postgrad Med 2009; 121(6): 148–157.
   PubMed Web of Science ®Google Scholar
• Sadovsky R, Kris-Etherton P. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides. Postgrad Med 2009; 121(4): 145–153.
   PubMed Web of Science ®Google Scholar
• Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92(3): 536–541.
   PubMed Web of Science ®Google Scholar
• Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000; 15(12): 1993–1999.
   PubMed Web of Science ®Google Scholar
• Sood A, Arora R. Mechanisms of flushing due to niacin and abolition of these effects. J Clin Hypertens (Greenwich) 2009; 11 (11): 685–689.
   PubMed Web of Science ®Google Scholar